The president of a large Belgian pharmaceuticals firm has been tapped to chair the board of directors of GaBio, a trade group that promotes the life sciences industry in Georgia.
Stephen Hill, the new board chair, leads Solvay Pharmaceuticals Inc., the Marietta-based U.S. subsidiary of Solvay, a global chemical and drug company with headquarters in Brussels, Belgium.
The American branch employs 9,000 people and had sales of 2.7 billion euros (nearly $4 billion) in 2008, according to its Web site. Dr. Hill leads the company's executive committee, serves on its board of directors and is president of all Solvay Pharmaceuticals subsidiaries, including Unimed Pharmaceuticals, Solvay Organics and Solvay Biologicals.
GaBio's nearly 300 members include universities, medical centers, research institutes, and pharmaceutical, biotech and medical device companies.
Thomas Callaway, CEO of Aerovectrx, has been named vice chair of the organization's board.
Founded in 2005 in Atlanta, Aerovectrx is developing aerosol vaccines and devices to deliver them. Dr. Callaway became CEO in April after three years on the company's board.
"Drs. Hill and Callaway provide GaBio's board of directors with the leadership to launch initiatives that can help our members succeed in their endeavors and make our state a premier location for life sciences industry development," said Charles Craig, GaBio president, in a news release.
For the full list of board members, visit www.gabio.org.